Log in

Relevant bibliographies by topics / Benralizumab / Journal articles

To see the other types of publications on this topic, follow the link: Benralizumab.

Journal articles on the topic 'Benralizumab'

Author: Grafiati

Published: 14 March 2023

Last updated: 11 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Benralizumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Antoniu, S. A. "Benralizumab." Drugs of the Future 39, no. 7 (2014): 463. http://dx.doi.org/10.1358/dof.2014.039.07.2156125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zhuravleva, M. V., S. N. Avdeev, Yu V. Gagarina, and T. V. Marin. "Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings." FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, no. 2 (2022): 175–86. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.143.

Full text

Abstract:

Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe asthma (SA).Material and methods. The cost minimization and budget impact analysis methods were used. The current practice of treating patients with SA with benralizumab in hospital settings at the expense of compulsory medical insurance funds was compared with the simulated practice. The simulated price was calculated as half patients receiving b

APA, Harvard, Vancouver, ISO, and other styles

3

Bourdin, Arnaud, Don Husereau, Nicolas Molinari, et al. "Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review." European Respiratory Journal 52, no. 5 (2018): 1801393. http://dx.doi.org/10.1183/13993003.01393-2018.

Full text

Abstract:

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised.We performed a matching-adjusted indirect comparison (MAIC) of benralizumab versus mepolizumab and reslizumab. Trials were selected through systematic review and evaluation of trial methods. Benralizumab patient-level data were weighted to match treatment-effect-modifying patient characteristics of comparator trials before indirect efficacy c

APA, Harvard, Vancouver, ISO, and other styles

4

Ando, Koichi, Akihiko Tanaka, and Hironori Sagara. "Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review." International Journal of Molecular Sciences 21, no. 3 (2020): 889. http://dx.doi.org/10.3390/ijms21030889.

Full text

Abstract:

No head-to-head trials have compared the efficacy and safety between the licensed dosage and administration dosage of dupilumab and benralizumab for inadequately controlled asthma. We conducted an indirect treatment comparison to estimate differences in the efficacy and safety between dupilumab and benralizumab for inadequately controlled asthma using the Bayesian approach. The primary efficacy endpoint was annual exacerbation rate (AER). A subgroup analysis by blood eosinophil count was also performed. The primary safety endpoint was the incidence of any adverse events (AAEs). The results dem

APA, Harvard, Vancouver, ISO, and other styles

5

Bleecker, Eugene R., Michael E. Wechsler, J. Mark FitzGerald, et al. "Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma." European Respiratory Journal 52, no. 4 (2018): 1800936. http://dx.doi.org/10.1183/13993003.00936-2018.

Full text

Abstract:

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma.This analysis used pooled data from the SIROCCO (ClinicalTrials.gov identifier NCT01928771) and CALIMA (ClinicalTrials.gov identifier NCT01914757) Phase III studies. Patients aged 12–75 years with severe, uncontrolled asthma receiving high-dosage inhaled corticosteroids plus long-acting β2-agonists received b

APA, Harvard, Vancouver, ISO, and other styles

6

Yamada, Hideyasu, Masayuki Nakajima, Masashi Matsuyama, et al. "Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma." PLOS ONE 16, no. 3 (2021): e0248305. http://dx.doi.org/10.1371/journal.pone.0248305.

Full text

Abstract:

Purpose To characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement. Patients and methods Sixty-four participants diagnosed with severe eosinophilic asthma and who had completed 4 months of benralizumab treatment were included in this analysis. Pre-treatment clinical factors were compared between responders and non-responders according to improvements in ACT or FEV1. Correlations between the sums of increased Type 2-related inflammatory parameters and changes of ACT or FE

APA, Harvard, Vancouver, ISO, and other styles

7

Titova, Olga N., Natalia A. Kuzubova, Daria B. Sklyarova, and Maria A. Petrova. "The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice." PULMONOLOGIYA 31, no. 5 (2021): 628–34. http://dx.doi.org/10.18093/0869-0189-2021-31-5-628-634.

Full text

Abstract:

To evaluate the effectiveness of benralizumab in patients with the eosinophilic phenotype of severe asthma in real clinical practice after a year of therapy.Methods. During Benralizumab therapy, 13 patients with severe eosinophilic asthma (average age – 55.44 ± 7.18 years old) were examined twice: before the treatment and after 1 year of benralizumab therapy. The assessment included collection of complaints, medical history, current therapy, Asthma Control Questionnaire (ACQ-5) test, absolute blood count of eosinophils, spirometry.Results. All patients initially had pronounced eosinophilia of

APA, Harvard, Vancouver, ISO, and other styles

8

Tsurumaki, Matsuyama, Ezawa, et al. "Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis." Medicina 55, no. 7 (2019): 336. http://dx.doi.org/10.3390/medicina55070336.

Full text

Abstract:

A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy. Six months after BT, a diagnosis of severe asthma with eosinophilic chronic rhinosinusitis (ECRS) was made and benralizumab treatment was initiated; the blood eosinophil count subsequently decreased and lung function improved, thereby permitting OCS dose tapering. Surprisingly, benralizumab both reduced nasal polyps and ameliorated ECRS. Thus, benralizumab may be a useful drug for the ra

APA, Harvard, Vancouver, ISO, and other styles

9

Nedogoda, Sergey Vladimirovich, Alla Sergeevna Salasyuk, Irina Nikolaevna Barykina, Victoria Olegovna Smirnova та Maksim Yurevich Frolov. "Сost of the Biologacal Therapy for Severe Brochcial Asthma Treatment at Inpatient and Day Care Setting". Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор), № 1 (39) (1 травня 2020): 61–69. http://dx.doi.org/10.31556/2219-0678.2020.39.1.061-069.

Full text

Abstract:

Objective: to assess the cost of the severe bronchial asthma (BA) treatment with various biological agents at inpatient and day care setting from the compulsory medical insurance (CMI) system perspective. Methods. The authors constructed the MS Excel® analytical decision-making model and calculated the CMI system’s costs of severe BA treatment with various biological drugs at inpatient and day care setting. The costs of treatment with benralizumab, dupilumab, omalizumab, reslizumab and mepolizumab were compared. The cost difference between benralizumab and other drugs was identified taking int

APA, Harvard, Vancouver, ISO, and other styles

10

Markham, A. "Benralizumab: First Global Approval." Drugs 78, no. 4 (2018): 505–11. http://dx.doi.org/10.1007/s40265-018-0876-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lombardo, Nicola, Corrado Pelaia, Marco Ciriolo, et al. "Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma." International Journal of Immunopathology and Pharmacology 34 (January 2020): 205873842095085. http://dx.doi.org/10.1177/2058738420950851.

Full text

Abstract:

The aim of this study has been to evaluate the efficacy of the IL-5 receptor blocker benralizumab on chronic rhinosinusitis with nasal polyposis (CRSwNP), associated with severe eosinophilic allergic asthma. Ten patients with severe eosinophilic allergic asthma and CRSwNP were enrolled. Sino-nasal outcome test (SNOT-22), numerical rating scale (NRS), endoscopic nasal polyp score, Lund Mackey CT (computed tomography) score, and blood eosinophil count were measured at baseline and after 24 weeks of treatment with benralizumab. All the above clinical, endoscopic, imaging, and hematological parame

APA, Harvard, Vancouver, ISO, and other styles

12

László, Nimród, Hédy Katalin Sárközy, Cristina Alexandra Man, et al. "The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)." Journal of Interdisciplinary Medicine 6, no. 3 (2021): 157–61. http://dx.doi.org/10.2478/jim-2021-0030.

Full text

Abstract:

Abstract Background: Monoclonal antibody therapy is currently an additional treatment option to reduce exacerbations and improve symptom control in patients with severe eosinophilic asthma (SEA) that is uncontrolled despite treatment with high-dose inhaled corticosteroids and long-acting beta-2 agonists. Benralizumab, a monoclonal antibody that binds to the interleukin-5 receptor (IL-5), significantly reduces symptoms and annual exacerbations, as well as the use of systemic corticosteroids in patients with SEA. However, few studies are available on the effectiveness of this biological treatmen

APA, Harvard, Vancouver, ISO, and other styles

13

Pintea, Irena, Ioana Adriana Muntean, Carmen Teodora Dobrican, Nicolae Miron, and Diana Deleanu. "Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS." Journal of Clinical Medicine 11, no. 22 (2022): 6642. http://dx.doi.org/10.3390/jcm11226642.

Full text

Abstract:

Benralizumab is a humanized recombinant mAb that binds to the interleukin 5 receptor (IL-5R) expressed on eosinophils and is approved for the treatment of severe eosinophilic asthma. There are a series of severe eosinophilic disorders that may benefit from this treatment, and it could be a life-saving therapy. In this paper, we present two severe patients with eosinophil-induced diseases that had a good resolution after one dose of Benralizumab 30 mg. The first case is a severe non-necrotizing eosinophilic vasculitis following critical COVID-19 disease and the second case is a DRESS (Drug Rash

APA, Harvard, Vancouver, ISO, and other styles

14

Pelaia, Corrado, Claudia Crimi, Santi Nolasco, et al. "Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy." Biomedicines 9, no. 12 (2021): 1822. http://dx.doi.org/10.3390/biomedicines9121822.

Full text

Abstract:

Background. The wide availability of monoclonal antibodies for the add-on therapy of severe asthma currently allows for the personalization of biologic treatment by selecting the most appropriate drug for each patient. However, subjects with overlapping allergic and eosinophilic phenotypes can be often eligible to more than one biologic, so that the first pharmacologic choice can be quite challenging for clinicians. Within such a context, the aim of our real-life investigation was to verify whether allergic patients with severe eosinophilic asthma, not adequately controlled by an initial biolo

APA, Harvard, Vancouver, ISO, and other styles

15

Cañas, José A., Marcela Valverde-Monge, José M. Rodrigo-Muñoz, et al. "Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma." Journal of Personalized Medicine 11, no. 2 (2021): 76. http://dx.doi.org/10.3390/jpm11020076.

Full text

Abstract:

Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rapidly. Biomarkers that predict the response to this drug are needed so that microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe eosinophilic asthmatic patients treated with benralizumab, and serum miRNAs were evaluated before and after treatment by semi-quantitative P

APA, Harvard, Vancouver, ISO, and other styles

16

Vitale, Carolina, Angelantonio Maglio, Corrado Pelaia, et al. "Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting." Journal of Clinical Medicine 12, no. 3 (2023): 985. http://dx.doi.org/10.3390/jcm12030985.

Full text

Abstract:

Patients with severe OCS-dependent asthma can be considered a subgroup of asthma patients with severe disease and great risk of complications, related to chronic OCS use. The introduction of biological drugs has represented a turning point in the therapeutic strategy for severe asthma, offering a valid alternative to OCS. Benralizumab, like other anti-IL-5 agents, has been shown to reduce exacerbations and OCS intake/dosage and improve symptom control and lung function. While these findings have also been confirmed in real-life studies, data on long-term efficacy are still limited. Methods: In

APA, Harvard, Vancouver, ISO, and other styles

17

Bernstein, Jonathan A., Umesh Singh, Marepalli B. Rao, Karen Berendts, Xiang Zhang, and Diya Mutasim. "Benralizumab for Chronic Spontaneous Urticaria." New England Journal of Medicine 383, no. 14 (2020): 1389–91. http://dx.doi.org/10.1056/nejmc2016395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cooke, W. Donald, and Abigail Tarr Cooke. "Eosinophilic cystitis treatment with benralizumab." Journal of Allergy and Clinical Immunology 145, no. 2 (2020): AB67. http://dx.doi.org/10.1016/j.jaci.2019.12.734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Murray, Toby, Ben Haagsma, and Andrew Chetwood. "Non-infective cystitis secondary to benralizumab immunotherapy." BMJ Case Reports 15, no. 1 (2022): e244733. http://dx.doi.org/10.1136/bcr-2021-244733.

Full text

Abstract:

This case study discusses a patient who presented with severe lower urinary tract symptoms and pain after commencing immunotherapy for eosinophilic asthma. Initial aetiology was presumed to be infective but cultures were negative. Cross-sectional imaging showed extensive perivesical and periprostatic stranding and inflammation. He was initially treated with antibiotics and anti-inflammatories but a lack of clinical improvement led to a rigid cystoscopy which identified an inflamed, oedematous urothelium which was biopsied. Histology demonstrated extensive, full thickness superficial detrusor i

APA, Harvard, Vancouver, ISO, and other styles

20

Sereda, V. P., D. A. Svirido, M. V. Komarov, Zhanna A. Mironova, and M. A. Nyoma. "Experience of using benralizumab in the treatment of patients with severe asthma in the clinical practice of pulmonologists in Saint-Petersburg." PULMONOLOGIYA 32, no. 5 (2022): 670–77. http://dx.doi.org/10.18093/0869-0189-2022-32-5-670-677.

Full text

Abstract:

The accumulation of clinical experience in the use of biologic therapy in patients with severe bronchial asthma (SBA) in real-world clinical practice with the possible identification of additional, previously undescribed clinical outcomes is of practical interest.The aim. To present the results of an observational study of using benralizumab in SBA in real clinical practice of pulmonologists in Saint-Petersburg.Methods. We present the results of more than 1 year of follow-up of 18 patients with eosinophilic SBA (12 women, 6 men, age from 28 to 74, average age 55.0 ± 11.9 years). The patients r

APA, Harvard, Vancouver, ISO, and other styles

21

Vantaggiato, Lorenza, Paolo Cameli, Laura Bergantini, et al. "Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment." Biomedicines 10, no. 4 (2022): 761. http://dx.doi.org/10.3390/biomedicines10040761.

Full text

Abstract:

Severe eosinophilic asthma is characterized by chronic airway inflammation, oxidative stress, and elevated proinflammatory cytokines, especially IL-5. Mepolizumab and benralizumab are both humanized IgG antibodies directed against IL-5 signaling, directly acting on eosinophils count. Together with the complexity of severe asthma classification and patient selection for the targeted treatment, there is also the urgency to clarify the follow-up of therapy to identify biomarkers, in addition to eosinophils, for the optimal duration of treatment, persistence of effectiveness, and safety. To this p

APA, Harvard, Vancouver, ISO, and other styles

22

Jauhiainen, Alexandra, Lieke E. J. M. Scheepers, Anne L. Fuhlbrigge, et al. "Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations." ERJ Open Research 6, no. 4 (2020): 00246–2020. http://dx.doi.org/10.1183/23120541.00246-2020.

Full text

Abstract:

BackgroundCompEx Asthma, a novel composite end-point combining severe exacerbations (SevEx) with asthma-worsening events, was recently developed. Further characterisation of CompEx Asthma is needed to illustrate the applicability of this end-point. The objective was to evaluate CompEx Asthma as a rate end-point to determine how seasonal and geographical factors impact this novel outcome.MethodsSeven 24–56-week randomised controlled trials of budesonide/formoterol (BUD/FORM) and benralizumab were analysed. Annualised event rates (AERs) and treatment effects (hazard ratio (HR)) were analysed wit

APA, Harvard, Vancouver, ISO, and other styles

23

Lacouture, Mario E., Alexander Pan, George Dranitsaris, et al. "Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer." Journal of Clinical Oncology 40, no. 16_suppl (2022): 12100. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.12100.

Full text

Abstract:

12100 Background: Rash associated with increased peripheral eosinophils develops in approximately 50% of metastatic breast cancer patients receiving alpelisib. Antihistamines and corticosteroids have limited benefit. Refractory rash may lead to decreased dose intensity and affect clinical outcome. Benralizumab is an anti-IL-5Rα chimeric monoclonal antibody that depletes peripheral eosinophils and has demonstrated benefit in eosinophilic asthma and hypereosinophilic syndrome. We investigate the efficacy and safety of benralizumab for the treatment of alpelisib rash. Methods: We performed a sing

APA, Harvard, Vancouver, ISO, and other styles

24

Lacouture, Mario E., Alexander Pan, George Dranitsaris, et al. "Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer." Journal of Clinical Oncology 40, no. 16_suppl (2022): 12100. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.12100.

Full text

Abstract:

12100 Background: Rash associated with increased peripheral eosinophils develops in approximately 50% of metastatic breast cancer patients receiving alpelisib. Antihistamines and corticosteroids have limited benefit. Refractory rash may lead to decreased dose intensity and affect clinical outcome. Benralizumab is an anti-IL-5Rα chimeric monoclonal antibody that depletes peripheral eosinophils and has demonstrated benefit in eosinophilic asthma and hypereosinophilic syndrome. We investigate the efficacy and safety of benralizumab for the treatment of alpelisib rash. Methods: We performed a sing

APA, Harvard, Vancouver, ISO, and other styles

25

Krysanov, I. S., V. S. Krysanova, and V. Yu Ermakova. "Th e clinical-economic analysis of Dupilumab in severe asthma." Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice, no. 5 (February 14, 2021): 15–26. http://dx.doi.org/10.37489/2588-0519-2020-5-15-26.

Full text

Abstract:

Background. Severe Asthma is a most social important chronic illness due to highest expenditures of Health Care System for control and treatment of exacerbations and decreasing of GDP. Situation with modern treatment is better now because biologic drugs have introduced into real practice. Biologic drugs — dupilumab, mepolizumab, reslizumab and benralizumab — decrease annual exacerbation rate of severe asthma as well as improve a lung function. Comparison of clinical-economic analyses of biologic drugs usage can help choose an optimal treatment technology of severe asthma. Materials and methods

APA, Harvard, Vancouver, ISO, and other styles

26

Miralles-López, Juan Carlos, Rubén Andújar-Espinosa, Francisco Javier Bravo-Gutiérrez, et al. "Analysis of response of severe eosinophilic asthmatic patients to benralizumab." Allergologia et Immunopathologia 50, no. 6 (2022): 163–68. http://dx.doi.org/10.15586/aei.v50i6.704.

Full text

Abstract:

Introduction: Clinical trials and real-life studies have been published showing effectiveness of benralizumab in severe eosinophilic asthmatic patients. The aim of the present study is to describe super-responders to benralizumab in a series of 79 patients who completed at least 1 year of treatment, and to compare super-responders with non super-responders. Methods: This is a multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed in eight hospitals under the conditions of routine clinical practice. Patients with zero exacerbations and no oral c

APA, Harvard, Vancouver, ISO, and other styles

27

Shimizu, Hideyasu, Masamichi Hayashi, Hisayuki Kato, Mitsuru Nakagawa, Kazuyoshi Imaizumi, and Mitsushi Okazawa. "IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma." International Journal of Molecular Sciences 22, no. 20 (2021): 11209. http://dx.doi.org/10.3390/ijms222011209.

Full text

Abstract:

A woman in her 50s was a super responder to benralizumab administered for the treatment of severe bronchial asthma (BA) with eosinophilic chronic rhinosinusitis with nasal polyp (ECRS) and eosinophilic otitis media (EOM). She exhibited the gradual exacerbation of ECRS/EOM despite good control of BA approximately 1 year after benralizumab initiation. Therefore, the treatment was switched to dupilumab, and the condition of the paranasal sinuses and middle ear greatly improved with the best control of her asthma. The patient reported that her physical condition was the best of her life. However,

APA, Harvard, Vancouver, ISO, and other styles

28

Laorden, Daniel, David Romero, and Javier Domínguez-Ortega. "Benralizumab in eosinophilic granulomatosis with polyangiitis." Medicina Clínica (English Edition) 158, no. 9 (2022): 441–42. http://dx.doi.org/10.1016/j.medcle.2021.07.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Sugino, Keishi, Hirotaka Ono, Akira Hebisawa, and Eiyasu Tsuboi. "Eosinophilic bronchiolitis successfully treated with benralizumab." BMJ Case Reports 14, no. 10 (2021): e246058. http://dx.doi.org/10.1136/bcr-2021-246058.

Full text

Abstract:

A 53-year-old non-smoking Japanese woman was admitted to our hospital with a 20-year history of wet cough and dyspnoea on exertion. Bronchial asthma (BA) had been diagnosed 20 years earlier. Although she has been treated with high-dose inhaled corticosteroid, she had experienced frequent exacerbation of BA, and short-term oral corticosteroid bursts were occasionally administered. High-resolution CT of the chest revealed diffuse centrilobular nodules with bronchial wall thickening and patchy ground-glass opacities in both lungs. Lung biopsy specimens showed widespread cellular bronchiolitis wit

APA, Harvard, Vancouver, ISO, and other styles

30

Matera, M. G., P. Rogliani, L. Calzetta, G. W. Canonica, and M. Cazzola. "Benralizumab for the treatment of asthma." Drugs of Today 53, no. 12 (2017): 633. http://dx.doi.org/10.1358/dot.2017.53.12.2736670.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kuang, Fei Li, Fanny Legrand, Michelle Makiya, et al. "Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome." New England Journal of Medicine 380, no. 14 (2019): 1336–46. http://dx.doi.org/10.1056/nejmoa1812185.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Saco, Tara Vinyette, Amber N. Pepper, and Richard F. Lockey. "Benralizumab for the treatment of asthma." Expert Review of Clinical Immunology 13, no. 5 (2017): 405–13. http://dx.doi.org/10.1080/1744666x.2017.1316194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Hussar, Daniel A., and Justin George. "Erenumab-aooe, Benralizumab, and Tezacaftor/ivacaftor." Journal of the American Pharmacists Association 58, no. 5 (2018): 579–82. http://dx.doi.org/10.1016/j.japh.2018.07.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Griscti Soler, Daniel, Alessandra Bennici, Silvia Brunetto, Sebastiano Gangemi, and Luisa Ricciardi. "Benralizumab in the management of rare primary eosinophilic lung diseases." Allergy and Asthma Proceedings 43, no. 6 (2022): 494–500. http://dx.doi.org/10.2500/aap.2022.43.220056.

Full text

Abstract:

Background: Eosinophils have a double-edged role in the human body, being essential in important physiologic functions but whose presence is conspicuous in a variety of diseases characterized by a T2 inflammation phenotype. Eosinophils are exquisitely sensitive to corticosteroids, and the latter have, until recently, represented the cornerstone of treatment of eosinophilic diseases. However, most patients remain dependent on oral corticosteroids, with a notable adverse effect burden and experience a chronic relapsing disease that leads to high morbidity and mortality. Treatment prospects have

APA, Harvard, Vancouver, ISO, and other styles

35

Wechsler, M., P. A. Merkel, S. Necander та ін. "AB0619 Rationale and Design of the 52-week, Randomized, Phase 3, Head-to-Head MANDARA Study to Evaluate the Efficacy and Safety of Benralizumab, a Humanized, Anti-interleukin–5 Receptor α Monoclonal Antibody in Refractory or Relapsing Eosinophilic Granulomatosis with Polyangiitis". Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1435.2–1436. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2075.

Full text

Abstract:

BackgroundEosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) is a rare, potentially organ- and life-threatening disease characterized by systemic eosinophilia, airway disease, and multi-system small-vessel vasculitis. Management of EGPA generally focuses on reducing active inflammation using corticosteroids and immunosuppressants, both of which are associated with serious adverse effects and incomplete disease control. High blood eosinophil (bEOS) levels are a central component of the pathophysiology of EGPA, and studies have shown that bEOS-reducing therapie

APA, Harvard, Vancouver, ISO, and other styles

36

Ignatova, G. L., V. N. Antonov, E. V. Blinova, I. V. Grebneva, and E. V. Sheklanova. "New therapy options for patients with eosinophilic type of severe bronchial asthma." Medical Council, no. 21 (January 28, 2020): 111–16. http://dx.doi.org/10.21518/2079-701x-2019-21-111-116.

Full text

Abstract:

The article provides data on the epidemiology of severe asthma. It defines the phenotype and endotype of bronchial asthma and classifies BA according to phenotype/endotype. The features of the eosinophilic phenotype of severe bronchial asthma are considered. Clinical characteristics of the patient corresponding to the prescription of benralizumab are presented. The algorithm of decision making by a doctor-therapist about patients’ referral to a pulmonologist for consideration of the biological therapy issue is given. The results of the main clinical studies to assess the efficacy and safety of

APA, Harvard, Vancouver, ISO, and other styles

37

Leuppi, Jörg D., Peter Schmid-Grendelmeier, Thomas Rothe, et al. "Benralizumab: Der IL-5-Rezeptor als Ziel bei schwerem eosinophilem Asthma." Praxis 108, no. 7 (2019): 469–76. http://dx.doi.org/10.1024/1661-8157/a003222.

Full text

Abstract:

Zusammenfassung. Für Patienten mit schwierig kontrollierbarem, schwerem Asthma bronchiale stehen heute neben der inhalativen Medikation hochwirksame, gezielte Behandlungsmöglichkeiten zur Verfügung. Bei Vorliegen einer deutlichen Eosinophilie verspricht die Hemmung der Interleukin-5-Achse (IL‑5) mit spezifischen, monoklonalen Antikörpern eine wirksame und nebenwirkungsarme Alternative zur dauerhaften systemischen Steroidtherapie. In diesem Übersichtsartikel werden die Daten zu Benralizumab, einem spezifischen Antikörper gegen den IL-5-Rezeptor Alpha, zusammengefasst. Dieser Angriffspunkt verhi

APA, Harvard, Vancouver, ISO, and other styles

38

Leuppi, Jörg D., Peter Schmid-Grendelmeier, Thomas Rothe, et al. "Benralizumab: Cibler le récepteur de l’IL-5 dans l’asthme sévère éosinophile." Praxis 108, no. 7 (2019): 1–8. http://dx.doi.org/10.1024/1661-8157/a003250.

Full text

Abstract:

Zusammenfassung. Für Patienten mit schwierig kontrollierbarem, schwerem Asthma bronchiale stehen heute neben der inhalativen Medikation hochwirksame, gezielte Behandlungsmöglichkeiten zur Verfügung. Bei Vorliegen einer deutlichen Eosinophilie verspricht die Hemmung der Interleukin-5-Achse (IL-5) mit spezifischen, monoklonalen Antikörpern eine wirksame und nebenwirkungsarme Alternative zur dauerhaften systemischen Steroidtherapie. In diesem Übersichtsartikel werden die Daten zu Benralizumab, einem spezifischen Antikörper gegen den IL-5-Rezeptor Alpha, zusammengefasst. Dieser Angriffspunkt verhi

APA, Harvard, Vancouver, ISO, and other styles

39

Menzella, Francesco, Mirco Lusuardi, Carla Galeone, Nicola Facciolongo, and Luigi Zucchi. "The clinical profile of benralizumab in the management of severe eosinophilic asthma." Therapeutic Advances in Respiratory Disease 10, no. 6 (2016): 534–48. http://dx.doi.org/10.1177/1753465816667659.

Full text

Abstract:

Despite several therapeutic choices, 10–20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phe

APA, Harvard, Vancouver, ISO, and other styles

40

Nolasco, Santi, Raffaele Campisi, Rossella Intravaia, et al. "Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use." F1000Research 9 (June 23, 2020): 637. http://dx.doi.org/10.12688/f1000research.24603.1.

Full text

Abstract:

Background: Monoclonal antibodies are a relatively new therapeutic option for patients with severe refractory asthma, which can be used as an add-on to maintenance therapy, reducing the need for systemic corticosteroid usage, improving asthma symptom control and reducing exacerbations. We report a case of a patient with severe refractory eosinophilic asthma, reluctant to take systemic steroids, who was successfully treated with benralizumab alone during an acute asthma attack. Case presentation: A 59-year-old Caucasian woman with a history of allergic asthma since childhood showed a progressiv

APA, Harvard, Vancouver, ISO, and other styles

41

Nolasco, Santi, Raffaele Campisi, Rossella Intravaia, et al. "Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use." F1000Research 9 (July 23, 2020): 637. http://dx.doi.org/10.12688/f1000research.24603.2.

Full text

Abstract:

Background: Monoclonal antibodies are a relatively new therapeutic option for patients with severe refractory asthma, which can be used as an add-on to maintenance therapy, reducing the need for systemic corticosteroid usage, improving asthma symptom control and reducing exacerbations. We report a case of a patient with severe refractory eosinophilic asthma, reluctant to take systemic steroids, who was successfully treated with benralizumab alone during an acute asthma attack. Case presentation: A 59-year-old Caucasian woman with a history of allergic asthma since childhood showed a progressiv

APA, Harvard, Vancouver, ISO, and other styles

42

Morimoto, Hiroki, Kensuke Fukuchi, Yasuaki Ogura, Masaki Ohtsuka, and Yoshiki Tokura. "Development of lichen planus following benralizumab treatment." European Journal of Dermatology 31, no. 2 (2021): 261–62. http://dx.doi.org/10.1684/ejd.2021.3995.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Engler, D. "M271 SEVERE EOSINOPHILIC CYSTITIS CONTROLLED WITH BENRALIZUMAB." Annals of Allergy, Asthma & Immunology 127, no. 5 (2021): S122. http://dx.doi.org/10.1016/j.anai.2021.08.388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Cushen, Breda, and Andrew Menzies-Gow. "Benralizumab: an updated treatment of eosinophilic asthma." Expert Review of Respiratory Medicine 14, no. 5 (2020): 435–44. http://dx.doi.org/10.1080/17476348.2020.1739526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Mishra, Ajay Kumar, Kamal Kant Sahu, and Atem James. "Disseminated herpes zoster following treatment with benralizumab." Clinical Respiratory Journal 13, no. 3 (2019): 189–91. http://dx.doi.org/10.1111/crj.12998.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Criner, Gerard J., Bartolome R. Celli, Christopher E. Brightling, et al. "Benralizumab for the Prevention of COPD Exacerbations." New England Journal of Medicine 381, no. 11 (2019): 1023–34. http://dx.doi.org/10.1056/nejmoa1905248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Fabbri, Leonardo M. "Benralizumab: for asthma, not yet for COPD." Lancet Respiratory Medicine 2, no. 11 (2014): 862–63. http://dx.doi.org/10.1016/s2213-2600(14)70225-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Dagher, Rania, Varsha Kumar, Alan M. Copenhaver, et al. "Novel mechanisms of action contributing to Benralizumab's potent anti-eosinophilic activity." European Respiratory Journal, July 21, 2021, 2004306. http://dx.doi.org/10.1183/13993003.04306-2020.

Full text

Abstract:

Benralizumab is a humanised, anti-IL-5Rα monoclonal antibody with anti-eosinophilic activity. Lack of fucose (afucosylation) increases its affinity to CD16a and significantly enhances antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells. Although benralizumab proved clinically efficacious in clinical trials for patients with severe asthma and hypereosinophilic syndrome, in-depth characterisation of its anti-eosinophilic mechanisms of action remain elusive. Here, we further investigated the mechanisms involved in benralizumab's anti-eosinophilic activities. In the presence of NK cel

APA, Harvard, Vancouver, ISO, and other styles

49

"Benralizumab." Reactions Weekly 1914, no. 1 (2022): 126. http://dx.doi.org/10.1007/s40278-022-18712-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Benralizumab." Reactions Weekly 1895, no. 1 (2022): 95. http://dx.doi.org/10.1007/s40278-022-10520-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!